Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
25 April 2024 - 2:30PM
Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or
“Elicio”), a clinical-stage biotechnology company developing a
pipeline of novel immunotherapies for the treatment of cancer,
today announced that it will be sharing new preliminary data from
the ongoing AMPLIFY-7P Phase 1/2 study in a poster presentation at
the 2024 American Society of Clinical Oncology (“ASCO”) Annual
Meeting, being held May 31-June 4, 2024 in Chicago, IL.
The AMPLIFY-7P study is evaluating the 7-peptide formulation of
Elicio’s off-the-shelf investigational therapeutic cancer vaccine
candidate, ELI-002 7P, in patients with mKRAS-driven solid tumors
that are positive for minimal residual disease. ELI-002 7P is
designed to stimulate an immune response against the seven KRAS
mutations that drive 25% of all solid tumors.
Presentation Details
ASCO 2024 Abstract Title: AMPLIFY-7P, a
first-in-human safety and efficacy trial of adjuvant mKRAS-specific
lymph node targeted amphiphile ELI-002 7P vaccine in patients with
minimal residual disease–positive pancreatic and colorectal
cancerAbstract Number: 2636Session Type
and Title: Poster Session – Developmental
Therapeutics—ImmunotherapySession Date and Time:
June 1, 2024, 9:00 AM-12:00 PM CDT (10:00 AM-1:00 PM
ET)Presenter: Craig E. Devoe, M.D., MHCM., Chief,
Division of Medical Oncology & Hematology, R.J Zuckerberg
Cancer Center, and Scientific Investigator, Northwell Health
About ELI-002 Our lead product candidate,
ELI-002, is a structurally novel investigational AMP cancer vaccine
that targets cancers that are driven by mutations in the
mKRAS-gene—a prevalent driver of many human cancers. ELI-002 is
comprised of two powerful components that are built with our AMP
platform consisting of AMP-modified mutant KRAS peptide antigens
and an AMP-modified CpG adjuvant that is available as an
off-the-shelf subcutaneous administration.
ELI-002 2P (2 peptide formulation) is currently being studied in
an ongoing Phase 1 (AMPLIFY-201) trial in patients with high
relapse risk mKRAS-driven solid tumors, following surgery and
chemotherapy (NCT04853017). ELI-002 7P (7 peptide formulation) is
currently being studied in a Phase 1/2 (AMPLIFY-7P) trial in
patients with mKRAS-driven pancreatic cancer (NCT05726864). The
ELI-002 7P formulation is designed to provide immune response
coverage against seven of the most common KRAS mutations present in
25% of all solid tumors, thereby increasing the potential patient
population for ELI-002 and potentially reducing the chance of
bypass resistance mechanisms.
About Elicio Therapeutics Elicio
Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology
company advancing a pipeline of novel lymph node-targeted
immunotherapies for the treatment of some of the most aggressive
cancers. By combining expertise in immunology and immunotherapy,
Elicio is harnessing the natural power of the immune system with
the Amphiphile (“AMP”) technology, which allows for therapeutic
payloads to be delivered directly to the lymph nodes, with the goal
of enhancing the immune system’s cancer-fighting capabilities. By
targeting cancer immunotherapies to the core of the immune
response, AMP aims to optimize the lymph nodes’ natural ability to
educate, activate and amplify cancer-specific T cells, which are
essential for recognizing and eliminating tumor cells. Engineered
to synchronize immunity in these highly potent sites, AMP is built
to enhance the magnitude, potency, quality and durability of the
immune response to drive antitumor activity. The Company’s R&D
pipeline includes off-the-shelf therapeutic cancer vaccines
ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and
ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations,
respectively). For more information, please visit
www.elicio.com.
Cautionary Note on Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). These include
statements regarding Elicio’s planned clinical programs, including
planned clinical trials, the potential of Elicio’s product
candidates, including the potential advantages of the ELI-002 7P
formulation, the expected participation and presentation at
upcoming conferences, and other statements regarding management’s
intentions, plans, beliefs, expectations or forecasts for the
future, and, therefore, you are cautioned not to place undue
reliance on them. No forward-looking statement can be guaranteed,
and actual results may differ materially from those projected.
Elicio undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise, except to the extent required by law.
We use words such as “anticipates,” “believes,” “plans,” “expects,”
“projects,” “future,” “intends,” “may,” “will,” “should,” “could,”
“estimates,” “predicts,” “potential,” “continue,” “guidance,” and
similar expressions to identify these forward-looking statements
that are intended to be covered by the safe-harbor provisions of
the PSLRA. Such forward-looking statements are based on our
expectations and involve risks and uncertainties; consequently,
actual results may differ materially from those expressed or
implied in the statements due to a number of factors, including,
but not limited to, Elicio’s plans to develop and commercialize its
product candidates, including ELI-002; the timing of the
availability of data from Elicio’s clinical trials, including the
timing of the availability of new preliminary data from the ongoing
AMPLIFY-7P Phase 1/2 study; Elicio’s plans to research, develop and
commercialize its current and future product candidates; and
Elicio’s ability to successfully collaborate with existing
collaborators or enter into new collaborations, and to fulfill its
obligations under any such collaboration agreements.
New factors emerge from time to time, and it is not possible for
Elicio to predict all such factors, nor can Elicio assess the
impact of each such factor on Elicio’s business or the extent to
which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any
forward-looking statements. These risks are more fully discussed in
the Annual Report on Form 10-K that was filed with the SEC on March
29, 2024, under the heading “Risk Factors”, and any subsequent
reports and other documents filed from time to time with the SEC.
Forward-looking statements included in this release are based on
information available to Elicio as of the date of this release.
Elicio does not undertake any obligation to update such
forward-looking statements to reflect events or circumstances after
the date of this release, except to the extent required by law.
Media ContactKristin PolitiLifeSci
Communicationskpoliti@lifescicomms.com646-876-4783
Investor Relations ContactHeather
DiVecchiaElicio TherapeuticsIR@elicio.com857-209-0153
Elicio Therapeutics (NASDAQ:ELTX)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Elicio Therapeutics (NASDAQ:ELTX)
Historical Stock Chart
Von Dez 2023 bis Dez 2024